Evidence that hepatic lipase deficiency in humans is not associated with proatherogenic changes in HDL composition and metabolism

Journal of Lipid Research

Volumn 45, Issue 8, 2004, Pages 1528-1537

  Ruel, Isabelle L ^a,b   Couture, Patrick ^b   Cohn, Jeffrey S ^c   Bensadoun, Andre ^d   Marcil, Michel ^e   Lamarche, Benoit ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^d Department of Obstetrics Gynecology   (United States)

^e ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Cholesterol efflux; High density lipoprotein; Kinetics

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LEUCINE; LIVER TRIACYLGLYCEROL LIPASE; TRITIUM;

ADULT; ARTICLE; ATHEROGENESIS; BODY MASS; CATABOLISM; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME DEFICIENCY; FEMALE; HUMAN; HUMAN CELL; HYPERTRIGLYCERIDEMIA; LIPID COMPOSITION; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MALE; MUTATION; PRIORITY JOURNAL; SKIN FIBROBLAST; STATISTICAL ANALYSIS; TWO DIMENSIONAL GEL ELECTROPHORESIS;

EID: 3442882762     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.M400090-JLR200     Document Type: Article

References (52)

1. Miller, G. J., and N. E. Miller. 1977. Plasma high density lipoprotein concentration and development of ischaemic heart disease. Lancet. 1: 16-18.
2. Durrington, P. N. 1993. How HDL protects against atheroma. Lancet. 342: 1315-1316.
3. Gordon, D. J., J. L. Probstfield, R. J. Garrison, J. D. Neaton, W. P. Castelli, J. Knoke, D. R. Jacobs, Jr., S. Bangdiwala, and H. A. Tyroler. 1989. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 79: 8-15.
4. Glomset, J. A. 1968. The plasma lecithins: cholesterol acyltransferase reaction. J. Lipid Res. 9: 155-167.
5. Fielding, C. J., and P. E. Fielding. 1995. Molecular physiology of reverse cholesterol transport. J. Lipid Res. 36: 211-228.
6. Kuusi, T., P. Saarinen, and E. A. Nikkila. 1980. Evidence for the role of hepatic endothelial lipase in the metabolism of plasma high density lipoprotein2 in man. Atherosclerosis. 36: 589-593.
7. Lamarche, B., K. D. Uffelman, A. Carpentier, J. S. Cohn, G. Steiner, P. H. Barrett, and G. F. Lewis. 1999. Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J. Clin. Invest. 103: 1191-1199.
8. Lamarche, B., S. Rashid, and G. F. Lewis. 1999. HDL metabolism in hypertriglyceridemic states: an overview. Clin. Chim. Acta. 286: 145-161.
9. Chen, G. C., W. Liu, P. Duchateau, J. Allaart, R. L. Hamilton, C. M. Mendel, K. Lau, D. A. Hardman, P. H. Frost, and M. J. Malloy. 1994. Conformational differences in human apolipoprotein B-100 among subspecies of low density lipoproteins (LDL). Association of altered proteolytic accessibility with decreased receptor binding of LDL subspecies from hypertriglyceridemic subjects. J. Biol. Chem. 269: 29121-29128.
10. McKeone, B. J., J. R. Patsch, and H. J. Pownall. 1993. Plasma triglycerides determine low density lipoprotein composition, physical properties, and cell-specific binding in cultured cells. J. Clin. Invest. 91: 1926-1933.
11. Toyota, Y., T. Yamamura, Y. Miyake, and A. Yamamoto. 1999. Low density lipoprotein (LDL) binding affinity for the LDL receptor in hyperlipoproteinemia. Atherosclerosis. 147: 77-86.
12. Fielding, P. E., C. J. Fielding, R. J. Havel, J. P. Kane, and P. Tun. 1983. Cholesterol net transport, esterification, and transfer in human hyperlipidemic plasma. J. Clin. Invest. 71: 449-460.
13. Morton, R. E., and D. B. Zilversmit. 1983. Inter-relationship of lipids transferred by the lipid-transfer protein isolated from human lipoprotein-deficient plasma. J. Biol. Chem. 258: 11751-11757.
14. Ahnadi, C. E., T. Masmoudi, F. Berthezene, and G. Ponsin. 1993. Decreased ability of high density lipoproteins to transfer cholesterol esters in non-insulin-dependent diabetes mellitus. Eur. J. Clin. Invest. 23: 459-465.
15. Lagrost, L. 1994. Regulation of cholesteryl ester transfer protein (CETP) activity: review of in vitro and in vivo studies. Biochim. Biophys. Acta. 1215: 209-236.
16. Skeggs, J. W., and R. E. Morton. 2002. LDL and HDL enriched in triglyceride promote abnormal cholesterol transport. J. Lipid Res. 43: 1264-1274.
17. Hegele, R. A., J. A. Little, C. Vezina, G. F. Maguire, L. Tu, T. S. Wolever, D. J. Jenkins, and P. W. Connelly. 1993. Hepatic lipase deficiency. Clinical, biochemical, and molecular genetic characteristics. Arterioscler. Thromb. 13: 720-728.
18. Breckenridge, W. C., J. A. Little, P. Alaupovic, C. S. Wang, A. Kuksis, G. Kakis, F. Lindgren, and G. Gardiner. 1982. Lipoprotein abnormalities associated with a familial deficiency of hepatic lipase. Atherosclerosis. 45: 161-179.
19. Connelly, P. W., G. F. Maguire, M. Lee, and J. A. Little. 1990. Plasma lipoproteins in familial hepatic lipase deficiency. Arteriosclerosis. 10: 40-48.
20. Connelly, P. W., S. Ranganathan, G. F. Maguire, M. Lee, J. J. Myher, B. A. Kottke, A. Kuksis, and J. A. Little. 1988. The beta very low density lipoprotein present in hepatic lipase deficiency competitively inhibits low density lipoprotein binding to fibroblasts and stimulates fibroblast acyl-CoA: cholesterol acyltransferase. J. Biol. Chem. 263: 14184-14188.
21. Carlson, L. A., L. Holmquist, and P. Nilsson-Ehle. 1986. Deficiency of hepatic lipase activity in post-heparin plasma in familial hyper-alpha- triglyceridemia. Acta Med. Scand. 219: 435-447.
22. Little, J. A., and P. W. Connelly. 1986. Familial hepatic lipase deficiency. Adv. Exp. Med. Biol. 201: 253-260.
23. Ruel, I. L., P. Couture, C. Gagne, Y. Deshaies, J. Simard, R. A. Hegele, and B. Lamarche. 2003. Characterization of a novel mutation causing hepatic lipase deficiency among French-Canadians. J. Lipid Res. 44: 1508-1514.
24. 2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin. Chem. 28: 1379-1388.
25. Couillard, C., J. P. Despres, B. Lamarche, J. Bergeron, J. Gagnon, A. S. Leon, D. C. Rao, J. S. Skinner, J. H. Wilmore, and C. Bouchard. 2001. Effects of endurance exercise training on plasma HDL cholesterol levels depend on levels of triglycerides: evidence from men of the Health, Risk Factors, Exercise Training and Genetics (HERITAGE) Family Study. Arterioscler. Thromb. Vasc. Biol. 21: 1226-1232.
26. Bensadoun, A. 1996. Sandwich immunoassay for measurement of human hepatic lipase. Methods Enzymol. 263: 333-338.
27. Pérusse, M., A. Pascot, J. P. Després, C. Couillard, and B. Lamarche. 2001. A new method for HDL particle sizing by polyacrylamide gradient gel electrophoresis using whole plasma. J. Lipid Res. 42: 1331-1334.
28. Cohn, J. S., D. A. Wagner, S. D. Cohn, J. S. Millar, and E. J. Schaefer. 1990. Measurement of very low density and low density lipoprotein apolipoprotein (Apo) B-100 and high density lipoprotein Apo A-I production in human subjects using deuterated leucine. Effect of fasting and feeding. J. Clin. Invest. 85: 804-811.
29. Batal, R., M. Tremblay, L. Krimbou, O. Mamer, J. Davignon, J. J. Genest, and J. S. Cohn. 1998. Familial HDL deficiency characterized by hypercatabolism of mature apoA-I but not proapoA-I. Arterioscler. Thromb. Vasc. Biol. 18: 655-664.
30. Cobelli, C., G. Toffolo, and D. M. Foster. 1992. Tracer-to-tracee ratio for analysis of stable isotope tracer data: link with radioactive kinetic formalism. Am. J. Physiol. 262: E968-E975.
31. Marcil, M., L. Yu, L. Krimbou, B. Boucher, J. F. Oram, J. S. Cohn, and J. Genest, Jr. 1999. Cellular cholesterol transport and efflux in fibroblasts are abnormal in subjects with familial HDL deficiency. Arterioscler. Thromb. Vasc. Biol. 19: 159-169.
32. Krimbou, L., M. Tremblay, J. Davignon, and J. S. Cohn. 1997. Characterization of human plasma apolipoprotein E-containing lipoproteins in the high density lipoprotein size range: focus on pre-beta1-LpE, pre-beta2-LpE, and alpha-LpE. J. Lipid Res. 38: 35-48.
33. Rashid, S., D. K. Trinh, K. D. Uffelman, J. S. Cohn, D. J. Rader, and G. F. Lewis. 2003. Expression of human hepatic lipase in the rabbit model preferentially enhances the clearance of triglycerideenriched versus native high-density lipoprotein apolipoprotein A-I. Circulation. 107: 3066-3072.
34. Fidge, N. H. 1999. High density lipoprotein receptors, binding proteins, and ligands. J. Lipid Res. 40: 187-201.
35. Jaye, M., K. J. Lynch, J. Krawiec, D. Marchadier, C. Maugeais, K. Doan, V. South, D. Amin, M. Perrone, and D. J. Rader. 1999. A novel endothelial-derived lipase that modulates HDL metabolism. Nat. Genet. 21: 424-428.
36. Gordon, D. J., and B. M. Rifkind. 1989. High-density lipoprotein- the clinical implications of recent studies. N. Engl. J. Med. 321: 1311-1316.
37. Miller, N. E. 1987. Associations of high density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am. Heart J. 113: 589-597.
38. Castro, G. R., and C. J. Fielding. 1988. Early incorporation of cell-derived cholesterol into pre-beta-migrating high-density lipoprotein. Biochemistry. 27: 25-29.
39. Kawano, M., T. Miida, C. J. Fielding, and P. E. Fielding. 1993. Quantitation of pre beta-HDL-dependent and nonspecific components of the total efflux of cellular cholesterol and phospholipid. Biochemistry. 32: 5025-5028.
40. Sviridov, D., and P. Nestel. 2002. Dynamics of reverse cholesterol transport: protection against atherosclerosis. Atherosclerosis. 161: 245-254.
41. Liang, H. Q., K. A. Rye, and P. J. Barter. 1994. Dissociation of lipid-free apolipoprotein A-I from high density lipoproteins. J. Lipid Res. 35: 1187-1199.
42. Liang, H. Q., K. A. Rye, and P. J. Barter. 1995. Cycling of apolipoprotein A-I between lipid-associated and lipid-free pools. Biochim. Biophys. Acta. 1257: 31-37.
43. Dichek, H. L., W. Brecht, J. Fan, Z. S. Ji, S. P. McCormick, H. Akeefe, L. Conzo, D. A. Sanan, K. H. Weisgraber, S. G. Young, J. M. Taylor, and R. W. Mahley. 1998. Overexpression of hepatic lipase in transgenic mice decreases apolipoprotein B-containing and high density lipoproteins. Evidence that hepatic lipase acts as a ligand for lipoprotein uptake. J. Biol. Chem. 273: 1896-1903.
44. Dugi, K. A., M. J. Amar, C. C. Haudenschild, R. D. Shamburek, A. Bensadoun, R. F. Hoyt, Jr., J. Fruchart-Najib, Z. Madj, H. B. Brewer, Jr., and S. Santamarina-Fojo. 2000. In vivo evidence for both lipolytic and nonlipolytic function of hepatic lipase in the metabolism of HDL. Arterioscler. Thromb. Vasc. Biol. 20: 793-800.
45. Durstenfeld, A., O. Ben-Zeev, K. Reue, G. Stahnke, and M. H. Doolittle. 1994. Molecular characterization of human hepatic lipase deficiency. In vitro expression of two naturally occurring mutations. Arterioscler. Thromb. 14: 381-385.
46. McCoy, M. G., G. S. Sun, D. Marchadier, C. Maugeais, J. M. Glick, and D. J. Rader. 2002. Characterization of the lipolytic activity of endothelial lipase. J. Lipid Res. 43: 921-929.
47. Asztalos, B. F., P. S. Roheim, R. L. Milani, M. Lefevre, J. R. McNamara, K. V. Horvath, and E. J. Schaefer. 2000. Distribution of ApoA-1-containing HDL subpopulations in patients with coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 20: 2670-2676.
48. Demant, T., L. A. Carlson, L. Holmquist, F. Karpe, P. Nilsson-Ehle, C. J. Packard, and J. Shepherd. 1988. Lipoprotein metabolism in hepatic lipase deficiency: studies on the turnover of apolipoprotein B and on the effect of hepatic lipase on high density lipoprotein. J. Lipid Res. 29: 1603-1611.
49. Karpe, F., G. Steiner, K. Uffelman, T. Olivecrona, and A. Hamsten. 1994. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis. 106: 83-97.
50. Cockerill, G. W., K. A. Rye, J. R. Gamble, M. A. Vadas, and P. J. Barter. 1995. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol. 15: 1987-1994.
51. Klimov, A. N., V. S. Gurevich, A. A. Nikiforova, L. V. Shatilina, A. A. Kuzmin, S. L. Plavinsky, and N. P. Teryukova. 1993. Antioxidative activity of high density lipoproteins in vivo. Atherosclerosis. 100: 13-18.
52. Nofer, J. R., M. Walter, B. Kehrel, S. Wierwille, M. Tepel, U. Seedorf, and G. Assmann. 1998. HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate. Arterioscler. Thromb. Vasc. Biol. 18: 861-869.